| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/27/2009 | EP1981874B1 Aminophenyl derivatives as novel inhibitors of histone deacetylase |
| 05/27/2009 | EP1968581A4 Tetracyclic kinase inhibitors |
| 05/27/2009 | EP1960403B1 Pyrrolotriazine kinase inhibitors |
| 05/27/2009 | EP1931338A4 Aerosol powder formulation comprising sieved lactose |
| 05/27/2009 | EP1912946B1 Pyridine derivatives as dipeptedyl peptidase inhibitors |
| 05/27/2009 | EP1912706A4 Novel 5-substituted indole derivatives as dipeptidyl peptidase iv (dpp-iv) inhibitors |
| 05/27/2009 | EP1878431A4 Medicinal agent for preventing progression of apoptotic and jugulating necrotic changes in the organism tissues |
| 05/27/2009 | EP1866286B1 Pyridine derivatives useful as inhibitors of pkc-theta |
| 05/27/2009 | EP1833826B1 Tricyclic delta-opioid modulators |
| 05/27/2009 | EP1807419B1 (2-carboxamido)(3-amino) thiophene compounds |
| 05/27/2009 | EP1789107B1 Medical stent provided with inhibitors of atp synthesis |
| 05/27/2009 | EP1749002B1 Pyrrole or imidazole amides for treating obesity |
| 05/27/2009 | EP1742923B1 Pyrazole phenyl derivatives as ppar activators |
| 05/27/2009 | EP1740173A4 Azabicyclo-octane inhibitors of iap |
| 05/27/2009 | EP1730141B1 Compounds for the treatment of diseases |
| 05/27/2009 | EP1725544B1 3-[4-heterocyclyl-1,2,3-triazol-1-yl]-n-aryl-benzamides as inhibitors of the cytokines production for the treatment of chronic inflammatory diseases |
| 05/27/2009 | EP1711158B1 Otic detergent composition for animals, with edta and chlorexhidine |
| 05/27/2009 | EP1694627B1 Novel ligands that are activators of the rar receptors, use in human medicine and in cosmetics |
| 05/27/2009 | EP1684720B1 Introducing aerosol into a ventilator circuit |
| 05/27/2009 | EP1663241B1 5-arylpyrimidines as anticancer agents |
| 05/27/2009 | EP1653935A4 Anti-inflammatory formulations |
| 05/27/2009 | EP1635770B1 Antifungal nail coat and method of use |
| 05/27/2009 | EP1622912B1 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists |
| 05/27/2009 | EP1615925B1 Imidazopyridine derivatives as melanocortin receptor agonists |
| 05/27/2009 | EP1601644B1 Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors |
| 05/27/2009 | EP1596852B1 Drugs containing substituted 2-aryl-aminoacetic acid compounds |
| 05/27/2009 | EP1594497B1 Sulfhydantoins as phosphate isosteres for use as phosphatase inhibitors in the treatment of cancer and autoimmune disorders |
| 05/27/2009 | EP1589958B1 Reduced dose of tolterodine for treating urinary disorders |
| 05/27/2009 | EP1578350B1 Sustained-release gel coated compositions |
| 05/27/2009 | EP1578214B1 Food composition comprising a satiety enhancing amount of triacylglycerol |
| 05/27/2009 | EP1519915B1 Tricyclic steroid hormone nuclear receptor modulators |
| 05/27/2009 | EP1487797B1 Hetero-bridge substituted 8-arylquinoline pde4 inhibitors |
| 05/27/2009 | EP1485080B1 Use of adapalene for the treatment of dermatological disorders |
| 05/27/2009 | EP1476163A4 Method of treating hiv infection by preventing interaction of cd4 and gp120 |
| 05/27/2009 | EP1408045B1 Novel galactosylceramide analogs and beta-glucocerebrosidase activators,external skin preparations and method of activating beta-glucocerebrosidase using the analogs |
| 05/27/2009 | EP1404304B1 Tablet comprising cetirizine and pseudoephedrine |
| 05/27/2009 | EP1351672B1 Fatty acid analogues for the treatment of inflammatory and autoimmune disorders |
| 05/27/2009 | EP1299086A4 Gels formed by the interaction of polyvinylpyrrolidone with chitosan derivatives |
| 05/27/2009 | EP1250140B1 Combination ofan abl-, pdgf-receptor- and/or kit receptor-tyrosine kinase inhibitor with an organic compound capable of binding to alpha1-acidic glycoprotein |
| 05/27/2009 | EP1244448B1 Novel methods for the treatment and prevention of ileus |
| 05/27/2009 | EP1235915B1 Transgenic mammals into which a period 1 promoter that confers rhythmical expression has been introduced |
| 05/27/2009 | EP1171424B1 Cyclo-alkyl substituted benzimidazoles and their use as parp inhibitors |
| 05/27/2009 | EP1130966B2 Antiparasitic formulations |
| 05/27/2009 | EP1003850B1 Inhibitors of dna immunostimulatory sequence activity |
| 05/27/2009 | EP0934287B1 Heterocyclic esters and amides |
| 05/27/2009 | EP0871487B1 Dendritic cell stimulatory factor |
| 05/27/2009 | CN101443349A Compounds and compositions as channel activating protease inhibitors |
| 05/27/2009 | CN101443344A Trehalose compound and pharmaceutical comprising the compound |
| 05/27/2009 | CN101443340A Peptidomimetic inhibitors of psma, compounds comprising them, and methods of use |
| 05/27/2009 | CN101443336A Cyclopropyl fused indolobenzazepine HVC ns5b inhibitors |
| 05/27/2009 | CN101443335A Thiazolyl dihydro-indazoles |
| 05/27/2009 | CN101443333A 36 -des (3 -methoxy-4 -hydroxycyclohexyl) 36 - (3 -hydroxycycloheptyl) derivatives of rapamycin for the treatment of cancer and other disorders |
| 05/27/2009 | CN101443332A Anti-viral pyrimidine nucleoside derivatives |
| 05/27/2009 | CN101443331A Triazolopyrazine derivatives useful as anti-cancer agents |
| 05/27/2009 | CN101443329A Polymorphs of n-(4-chloro-3-methyl-5-isoxazolyl) 2-[2-methyl-4,5-(methylenedioxy)phenylacetyl] thiophene-3-sulfonamide, sodium salt |
| 05/27/2009 | CN101443328A Cocrystal of C-glycoside derivative and L-proline |
| 05/27/2009 | CN101443327A Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof |
| 05/27/2009 | CN101443326A Substituted prolinamides, production thereof and their use as drugs |
| 05/27/2009 | CN101443325A 2, 4 -diamino pyrimidines as cell cycle kinase inhibitors |
| 05/27/2009 | CN101443324A Benzylamine derivatives as CETP inhibitors |
| 05/27/2009 | CN101443323A Substituted spirocyclic CGRP receptor antagonists |
| 05/27/2009 | CN101443322A Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
| 05/27/2009 | CN101443321A Substituted chromanol derivatives and their use |
| 05/27/2009 | CN101443320A Bezothiazol derivatives as beta2 adrenoreceptor agonists |
| 05/27/2009 | CN101443316A 1,5-diphenylpyrazoles II as HSP90 inhibitors |
| 05/27/2009 | CN101443315A Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| 05/27/2009 | CN101443314A Aminoquinolones as GSK-3 inhibitors |
| 05/27/2009 | CN101443312A 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions |
| 05/27/2009 | CN101443311A 1H-indol-5-yl-piperazin-1-yl-methanone derivatives |
| 05/27/2009 | CN101443309A IAP BIR domain binding compounds |
| 05/27/2009 | CN101443292A New method for the manufacture of therapeutic compounds and compositions, compounds and compositions produced therewhith, and their use |
| 05/27/2009 | CN101443079A Antibacterial extracellular polysaccharide solvating system |
| 05/27/2009 | CN101443049A Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis |
| 05/27/2009 | CN101443048A Dendritic polymers with enhanced amplification and interior functionality |
| 05/27/2009 | CN101443045A Agent-enriched nanoparticles based on hydrophilic proteins |
| 05/27/2009 | CN101443039A Compositions and methods for immunisation using CD1D ligands |
| 05/27/2009 | CN101443026A Composition comprising at least one higher aliphatic alcohol and an extract of Griffonia simplicifolia |
| 05/27/2009 | CN101443022A Use of a growth-stimulating protein |
| 05/27/2009 | CN101443021A Prevention and treatment of cancer and other diseases |
| 05/27/2009 | CN101443020A RNAi-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions |
| 05/27/2009 | CN101443019A Use of cholest-4-in-3-in-one derivatives to obtain a cytoprotective medicine |
| 05/27/2009 | CN101443018A Sterilized nanoparticulate glucocorticosteroid formulations |
| 05/27/2009 | CN101443017A Medication against breast cancer and related diseases |
| 05/27/2009 | CN101443016A Use of 4, 17 beta-dihydroxyandrost-4-ene-3-one for treating cancers |
| 05/27/2009 | CN101443015A Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty |
| 05/27/2009 | CN101443014A Chemical compounds |
| 05/27/2009 | CN101443013A Pyrazolo [3,4-d] pyrimidine derivatives useful to treat respiratory disorders |
| 05/27/2009 | CN101443012A Azoxystrobin formulations |
| 05/27/2009 | CN101443011A Use of flibanserin for the treatment of post-menopausal sexual desire disorders |
| 05/27/2009 | CN101443010A Brain function-improving agent, and functional food containing the improving agent |
| 05/27/2009 | CN101443009A Antitumor agent for thyroid cancer |
| 05/27/2009 | CN101443008A Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin |
| 05/27/2009 | CN101443007A TEREPHTHALAMATE compounds and compositions, and their use as HIV integrase inhibitors |
| 05/27/2009 | CN101443006A Novel benzylamine derivatives as CETP inhibitors |
| 05/27/2009 | CN101443005A Immune response modifier formulations and methods |
| 05/27/2009 | CN101443004A Formulations and methods for vascular permeability-related diseases or conditions |
| 05/27/2009 | CN101443003A Triazole derivatives II |
| 05/27/2009 | CN101443002A Combination comprising an iron chelator and an anti-neoplastic agent and use thereof |
| 05/27/2009 | CN101443001A Method of treatment or prophylaxis inflammatory pain |
| 05/27/2009 | CN101443000A Xanthone derivative for the treatment of muscular disorders |